The United Kingdom’s National Physical Laboratory (NPL) has worked with Creavo Medical Technologies to better understand the performance and characteristics of our Corsens® imaging technology.  As part of NPL’s Measurement for Recovery (M4R) programme NPL have worked closely with Creavo scientists to review and independently verify the design and performance of the proprietary sensor technology using the laboratory’s highly specialised measurement facilities. Creavo Operations Director Andrew Mullen commented, “this type of independent measurement and quantification of the sensor performa ..read more

Creavo Medical Technologies Ltd (Creavo), the medical device company developing innovative diagnostics techniques, has announced that it has appointed Martin Frost as Chairman of the Board of Directors. In this role, Martin will drive Creavo’s fundraising plans, and guide its strategy to scale the business and commercialise its diagnostic technologies. Creavo has designed and built a platform device to map and analyse the magnetic fields of the heart. Based on this platform, the Company is developing Corsens, a medical device intended to be used by non-specialist staff to scan patients through ..read more

In recent years there has been a hugely concerted effort among medical technology companies, policymakers and the global cardiology community to tackle the prevention and treatment of heart disease. Despite these advancements, coronary heart disease remains a leading cause of death globally and in the UK. We are living through one of the most uncertain times in recent history. In the UK, despite the largest ever NHS funding package being pledged, the service is hugely stretched – resulting in record A&E waiting times among a host of other challenges. The British Heart Foundations National ..read more

By Steve Parker, CEO, Creavo Medical Technologies   Creavo has officially completed the 12-week Philips HealthWorks global collaboration programme, hosted at Philips’ Innovation Hub in Eindhoven in the Netherlands. The experience has been invaluable for our business as we finalise development of our device Corsens® and look towards making it commercially available. Creavo was one of only two European companies involved in the intensive programme which was aimed at exploring future collaboration. We worked alongside a specially selected group of 15 global emerging entrepreneurial companies that ..read more

By Steve Parker, CEO, Creavo Medical Technologies   The last 12 months were pivotal for Creavo in defining the roadmap for the final development phase for Corsens®. And with a new and important year for us already in full swing, our focus is on applying what we learned in 2019 and readying our potentially ground-breaking device for use by clinicians. In the final part of last year we embarked on an exciting partnership with Phillips HealthWorks as one of only two European companies involved in a three-month intensive programme to explore future collaborations. Phillips provided extremely valua ..read more

22 November 2019: UK medical device company Creavo Medical Technologies (Creavo) has begun a pioneering 510-patient study with University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, to evaluate the role of magnetocardiography (MCG) in the prediction of ventricular arrhythmias in patients who have been identified at risk of sudden cardiac death (SCD). Led by Dr Tom Lachlan, Research Fellow in Cardiology at UHCW, under the supervision of Professor Faizel Osman, Consultant Cardiologist / Electrophysiologist at UHCW, the study will involve performing MCG scans – which generate a magnetic ..read more

The British Medical Association (BMA) has predicted that the NHS may be about to experience its worst ever winter crisis, as more than 1 million NHS patients could face long waits in emergency departments. Following this, official figures have revealed that the target for A&E departments to see 95% of patients within four hours has not been met for four years now. Winter months bring extreme weather conditions that affect almost every segment of our population – in particular, the vulnerable and elderly. Coupled with an ageing population which is developing growing health issues – such as ..read more

We are now about halfway through the 12 week Philips HealthWorks global collaboration programme, which sees one of the largest multinational businesses in health technology working alongside a specially selected group of 15 global emerging entrepreneurial companies towards a shared goal of accelerating innovation. It has been a challenging and very rewarding journey so far and Creavo is proud to be one of only two European companies invited to be part of the #PhilipsHealthWorks programme. I’m looking forward to Creavo and Philips exp ..read more

By Dr Richard Charles October is Sudden Cardiac Arrest (SCA) awareness month – an annual campaign which raises awareness of the condition that affects 100,000 people in the UK each year. Unlike a heart attack, which is caused by impeded blood flow through the heart, SCA is caused by a structural or electrical problem with the heart, usually as a result of an underlying condition. For up to fifty per cent of those that suffer SCA, it is the first indication that there is anything wrong with their heart. As such, there has been a concerted focus among health authorities in the UK and globally on ..read more

World Heart Day on 29th of September provides an important opportunity to pause and reflect on the challenges we face in cardiology, and ways of addressing them. In particular, last year more than 1.3 million UK emergency department (ED) admissions were due to chest pain, but of these a significant proportion proved to have no serious cardiac-related condition. This resulted in blockages within over-stretched ED departments and delays in treatment for those that need it most urgently. When a patient presents at an ED with chest pain, traditional ECGs often can’t conclusively rule out cardiac-r ..read more